Real world experience with early bortezomib therapy in multiple myeloma in Australia suggests that it is used in patients who are older and more...
Day: 22 May 2020
Article of the week: Once-versus twice-weekly car fi lzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis
Myeloma Australia's Medical and Scientific Advisory Group (MSAG)Â presents the article of the week. Multiple myeloma (MM) is the third most common...